恩瑞特药业阿尔茨海默病新药获批上市；热景生物拟斥1亿元~2亿元回购股份丨医药早参

Group 1 - Huzhou Bio plans to repurchase shares worth 100 million to 200 million yuan, using its own funds, to stabilize stock prices and incentivize core talent [1] - The repurchase will cover 409,837 to 819,672 shares, accounting for 0.44% to 0.88% of the total share capital, and will be completed within 12 months [1] Group 2 - Enrite Pharmaceuticals' new drug, Memantine Hydrochloride Orally Disintegrating Tablets, has been approved for the treatment of moderate to severe Alzheimer's disease [2] - This drug is a novel NMDA receptor antagonist that protects nerve cells and promotes cognitive function recovery, filling a gap in the domestic market for this dosage form [2] Group 3 - Novartis' Remibrutinib has received FDA approval for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic after H1 antihistamine treatment [3] - Remibrutinib is the first BTK inhibitor approved by the FDA for CSU, providing a new treatment option by targeting the BTK signaling pathway to inhibit the release of histamine and other pro-inflammatory mediators [3]